Assent of Assignees Statement under 37 CFR 3.73(b)

Application No.: 10/699,563 Docket No.: 5998-0506PUS3

Docket No.: 5998-0506PUS3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bradford Van Wagenen et al.

Application No.: 10/699,563 Confirmation No.: 1604

Filed: November 3, 2003 Art Unit: 1625

For: HETEROPOLYCYCLIC COMPOUNDS AND

THEIR USE AS METABOTROPIC

GLUTAMATE RECEPTOR ANTAGONISTS

Examiner: Z. N. Davis

ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.

Address: 383 Colorow Drive

Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

1 ADM/Ic

Application No.: 10/699,563 Docket No.: 5998-0506PUS3

. NAMES AND SIGNATURES OF ASSIGNEES		
AstraZeneca AB	By: Name: Title:	Date:
II. NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

III. NAMES AND SIGNATURES OF ASSIGNEES				
NPS Pharmaceuticals, Inc.	By: Buton W. Giddings Title: Assistant Corporate secretary	Date: パルー フ-200 ら		
IV. NAMES AND SIGNATURES OF WITNESSES				
Name: Lesive Lancaster	Signature: Www.lmust	Date: 12.1.2005		
Name: Traci Myarkind	Signature: The state of the sta	Date: 12-7-2005		

2 ADM/lc

		S	TATEMENT	UNDER 37	CFR 3.73(I	<u>b)</u>		
Applicant:		Bradfo	rd Van Wagene	n et al.				
Application	No.:		10/699,563		Filed Date: _	P	November 3, 2	003
Entitled:		OLYCYCLIO R ANTAGO	COMPOUNDS	S AND THEIR	USE AS MET	ABOTE	ROPIC GLUTA	MATE
(Name of	PS PHARMA Assignee)	ACEUTICAL	S, Inc.	a (Type of Assign	C ee, e.g., corporation,	orporat partnersh	ion p, university, govern	ment agency, etc.)
states that	it is:							
1.	the assignee	of the entire	e right, title, and	interest; or				
2. X	an assignee	of less than	the entire right,	title and inter	est.			
	The extent (b	by percentag	ge) of its owners	ship interest is	50 9	%		
in the pate	nt application	√patent ider	ntified above by	virtue of eithe	r:			
			ventor(s) of the d States Patent				above. The as 012758 .	ssignment
	rame		, and for which other relevant a		of is attached.	Also at	tached are cop	oles of two
	chain of title ssignee as sl		ventor(s), of the	patent applic	ation/patent ide	entified	above, to the o	current
1	. From:				Го:			
			ecorded in the U					ad
_			_ , FIAIII0			opy use	neoi is allacine	fu.
2	. From:	iment was r	ecorded in the U		「o: Patent and Tra	demad	Office at	
			_ , Frame					ed.
3	. From:				Го:			
	The doc	ument was r	ecorded in the U	Jnited States	Patent and Tra	ademari	c Office at	
	Reel _		_ , Frame	,	or for which a c	copy the	ereof is attache	ed.
	Additional	documents	in the chain of ti	itle are listed	on a suppleme	ntal she	et.	
[NOTE: A seponded to A seconded in the condection of the condection of the condection the condection of	parate copy Assignment in e records of	other document (i.e., a true copy Division in accor the USPTO. <u>S</u>	/ of the origin: rdance with 3 <u>ee</u> MPEP 302	al assignment o 7 CFR Part 3, i 2.08]	docume if the as	signment is to	be
			pplied below) is					information and
belief are t	elieved to be t made are puni	rue; and furth shable by fine	de herein of my o er that these state e or imprisonment, eopagize the vali	ements were ma , or both, under	ade with the know Section 1001 of	wledge t Title 18	hat willful false s of the United St	itatements and
	3,1	m W/	1.11.	,		4	WUM27	2006
		Signa	ture ()				Date	
		Barton W.	Giddings				801-583-4949	
		Printed or Ty	ped Name			T	elephone Numb	er
	As		rate Secretary		- .			
		Titi	10					

Birch, Stewart, Kolasch & Birch, LLP ADM/IC

Application No.: 10/699,563 Docket No.: 5998-0506PUS3

Docket No.: 5998-0506PUS3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Bradford Van Wagenen et al.

Application No.: 10/699,563 Confirmation No.: 1604

Filed: November 3, 2003 Art Unit: 1625

For: HETEROPOLYCYCLIC COMPOUNDS AND

THEIR USE AS METABOTROPIC

GLUTAMATE RECEPTOR ANTAGONISTS

Examiner: Z. N. Davis

ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.

Address: 383 Colorow Drive

Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

1 ADM/Ic

Application No.: 10/699,563 Docket No.: 5998-0506PUS3

I. NAMES AND SIGNA	ATURES OF ASSIGNEES	
AstraZeneca AB	By:	Date:
	Title: Director IP Finance & IS	
II. NAMES AND SIGNA	ATURES OF WITNESSES	
Name: Ann-Sofie Sternås	Signature: While I	Date:
Name: Sonya Celebioglu	Signature: ()	Date:
III. NAMES AND SIGNA	ATURES OF ASSIGNEES	
NPS Pharmaceuticals, Inc.	By:	Date:
	Name:	
	Title:	
IV. NAMES AND SIGNA	ATURES OF WITNESSES	
Name:	Signature:	Date:
Name:	Signature:	Date:

2 ADM/lc

STATEMENT UNDER 37 CFR 3.73(b) Applicants: Bradford Van Wagenen et al. Application No.: 10/699,563 Filed Date: November 3, 2003 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE Entitled: RECEPTOR ANTAGONISTS **ASTRAZENECA AB** Corporation (Name of Assignee) states that it is: the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is 50 in the patent application/patent identified above by virtue of either: An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012758 , and for which a copy thereof is attached. Also attached are two other 0798 relevant assignments. OR A chain of title from the inventor(s), of the patent application/patent identified above, to the current B. assignee as shown below: 1. From: The document was recorded in the United States Patent and Trademark Office at _____, Frame _____, or for which a copy thereof is attached. 2. From: The document was recorded in the United States Patent and Trademark Office at , Frame _____, or for which a copy thereof is attached. 3. From: To: The document was recorded in the United States Patent and Trademark Office at , Frame , or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. X Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Signature Date Bo Hasslev Printed or Typed Name Telephone Number Director, IP Finance & Info. Title

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto each of

AstraZeneca AB SE-151 85 Södertälje, Sweden

AND

NPS Pharmaceuticals, Inc. 383 Colorow Drive Salt Lake City, Utah 84108 United States of America

(hereinafter referred to singly and collectively as "ASSIGNEE") their successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE,

its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of BIRCH, STEWART, KOLASCH & BIRCH, LLP, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of BIRCH, STEWART, KOLASCH & BIRCH, LLP, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NA	MES AND SIGNATURES OF A	ASSIGNEES	
AstraZeneca AB	By:	Date:	
	Name:		
	Title:		
NAMES AND SIGNATURES OF WITNESSES			
Name:	Signature:	Date:	
Name:	Signature:	Date:	

NAM	ES AND SIGNATURES OF AS	SIGNEES
NPS Pharmaceuticals, Inc.	By:	Date:
	Name:	
	Title:	
NAM	ES AND SIGNATURES OF WI	TNESSES
Name:	Signature:	Date:
Name:	Signature:	Date:

Name: Ian EGLE	Signature:	Date:	
c/o NPS Allelix Corp.			
6850 Goreway Drive			
Mississauga, Ontario, L4V			
1V7 Canada			
NA	MES AND SIGNATURES OF	F WITNESSES	
Name:	Signature:	Date:	
Name:	Signature:	Date:	

NAMES AND SIGNATURES OF INVENTORS				
Name: Louise EDWARDS c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:		
	ES AND SIGNATURES OF WITNESSES	5		
Name:	Signature:	Date:		
Name:	Signature:	Date:		

NAMES AND SIGNATURES OF INVENTORS				
Name: Tomislav	Signature:	Date:		
STEFANAC				
c/o NPS Allelix Corp.				
6850 Goreway Drive				
Mississauga, Ontario, L4V				
1V7 Canada				
NAM	ES AND SIGNATURES OF WITNESSES	5		
Name:	Signature:	Date:		
Name:	Signature:	Date:		

NAMES AND SIGNATURES OF INVENTORS				
Name: Tao XIN	Signature:	Date:		
c/o NPS Allelix Corp.				
6850 Goreway Drive				
Mississauga, Ontario, L4V				
1V7 Canada				
NAMI	ES AND SIGNATURES OF	WITNESSES		
Name:	Signature:	Date:		
Name:	Signature:	Date:		

NAMES AND SIGNATURES OF INVENTORS				
Name: Jalaj ARORA c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Signature:	Date:		
NAMES AND SIGNATURES OF WITNESSES				
Name:	Signature:	Date:		
Name:	Signature:	Date:		

NAMES AND SIGNATURES OF INVENTORS		
Signature:	Date:	
Link The	102/25	
Villam & Wehne	12/23/03	
	,	
ES AND SIGNATURES OF WITNESSES	5	
Signature: The Chansen	Date: 12 \$3/05	
Signature Challet A Millar	Date: 1.2/23/05	
	Signature: William f. Wiehne ES AND SIGNATURES OF WITNESSES	

ASSIGNMENT – WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto each of

AstraZeneca AB SE-151 85 Södertälje, Sweden

AND

NPS Pharmaceuticals, Inc.
383 Colorow Drive
Salt Lake City, Utah 84108 United States of America

(hereinafter referred to singly and collectively as "ASSIGNEE") their successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE,

its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH**, **STEWART**, **KOLASCH & BIRCH**, **LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of BIRCH, STEWART, KOLASCH & BIRCH, LLP, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAMES AND SIGNATURES OF ASSIGNEES		
AstraZeneca AB	By:	Date:
	Name:	
	Title:	
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

NAMES AND SIGNATURES OF ASSIGNEES		
NPS Pharmaceuticals, Inc.	By: Edward + Nimble	Date: 8 Du 05
	Name: Edward F. Nemeth	
	Title: Chief Scientific Office?	
NAMES AND SIGNATURES OF WITNESSES		
Name: Tereson A Book	Signature:	Date: Derber 8, 2005
Name: Lisowsky Snezana	Signature: Lionsky Snezana	Date: December 2 1005
<u> </u>		

NAMES AND SIGNATURES OF INVENTORS		
Name: Ian EGLE	Signature:	Date:
c/o NPS Allelix Corp.		/
6850 Goreway Drive	1/1/1/2//	Dec. 7/05
Mississauga, Ontario, L4V		0 200 /
1V7 Canada		
NAMI	ES AND SIGNATURES OF WITNESSES	S .
Name: Fresh A. Beck	Signature:	Date: Derby 7/05
Name: Fresh A. Beck Name: Snežana Lisowsky	Signature: Inexana Lisowsky	Date: December 7,05
		

NAMES AND SIGNATURES OF INVENTORS		
Name: Louise EDWARDS	Signature:	Date:
c/o NPS Allelix Corp. 6850 Goreway Drive Mississauga, Ontario, L4V 1V7 Canada	Lahoard	Dec7/05
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresu A. Beck	Signature:	Date: De by 72005
Name: Snežana Lisowsky	Signature: Ingrana Lisowsky	Date: December 1, 65
	//	

NAMES AND SIGNATURES OF INVENTORS		
Name: Tomislav	Signature:	Date:
STEFANAC	5	
c/o NPS Allelix Corp.	Jomislar Stefanoc	Dec. 7,2005
6850 Goreway Drive	(
Mississauga, Ontario, L4V		
1V7 Canada		
NAMES AND SIGNATURES OF WITNESSES		
Name: Person A. Beck	Signature:	Date: Declar 7 2005
Name: Dec. 7. 2005	Signature:	Date: Dec. 7, 2005

TAO XIN

NAMES AND SIGNATURES OF INVENTORS		
Name: Tao XIN	Signature:	Date:
c/o NPS Allelix Corp.		
6850 Goreway Drive		Dec. 7. 2005
Mississauga, Ontario, L4V		
1V7 Canada		
NAMES AND SIGNATURES OF WITNESSES		
Name: Teresa A. Beck	Signature:	Date: December 7 05
Name: Lisowsky Snežana	Signature: Lisowsky Incomer	Date: December 7, 05

NAMES AND SIGNATURES OF INVENTORS		
Name: Jalaj ARORA	Signature:	Date:
c/o NPS Allelix Corp.	7 7 1/1 - 200.	
6850 Goreway Drive	= a a a a	Dec. 07/05
Mississauga, Ontario, L4V		1 - 6 - 1,703
1V7 Canada	7 0	
NAMI	ES AND SIGNATURES OF WITNESSE	ES .
Name: Taresa A Beck	Signature:	Date: Denber 7 2005
Name: 100. 7- 2005 14	Signature:	Date: Dec. 7. 2005
TAO XIN		

Name: William F.
MICHNE
c/o AstaZeneca AB
SE-151 85
Södertälje, Sweden

NAMES AND SIGNATURES OF WITNESSES
Name:
Signature:
Date:

Name:
Signature:
Date:

Date:

Date:

Date:

Date:

Date:

Date:

Date:

ASSIGNMENT – WORLDWIDE

Whereas, the inventors, Bradford C. VAN WAGENEN, Thomas M. STORMANN, Scott T. MOE, Susan M. SHEEHAN, Donald A. MCLEOD, Daryl M. SMITH all of Salt Lake City, Utah in the United States; and Methvin B. ISAAC, and Abdelmalik SLASSI of Mississauga, Ontario, Canada, by an assignment recorded April 2, 2002 at Reel 012758, Frames 0798-0800, have assigned their full and exclusive right in and to the invention set forth in U.S. Application Serial No. 10/076,618 filed February 19, 2002 and entitled HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS to: NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America, this present address of NPS Pharmaceuticals having changed from 420 Chipeta Way, Salt Lake City, Utah, USA;

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned acting with proper authority on behalf of NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto

AstraZeneca AB SE-151 85 Södertälje, Sweden

(hereinafter referred to as "ASSIGNEE") its successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	CO
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JP
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to

ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH**, **STEWART**, **KOLASCH** & **BIRCH**, **LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of BIRCH, STEWART, KOLASCH & BIRCH, LLP, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NA	MES AND SIGNATURES OF ASSIGNOR	
NPS Pharmaceuticals, Inc.	By: /Satmw Muly Name: Barton W. Giddings	Date: 12-7-2005
	Title: Assistant Corporate secretary	
NAMES AND SIGNATURES OF WITNESSES		
Name: Leslie Lancaster	Signature: Win of Imanta	Date: 17-7-2005
Name: Traci McFarland	Signature: Ju- m	Date: 12-7-2005

Λ	IAMES AND SIGNATURES (OF ASSIGNEE
AstraZeneca AB	By:	Date:
	Name:	
	Title:	
N.	AMES AND SIGNATURES O	F WITNESSES
Name:	Signature:	Date:
Name:	Signature:	Date:

ASSIGNMENT – WORLDWIDE

Whereas, the inventors, Bradford C. VAN WAGENEN, Thomas M. STORMANN, Scott T. MOE, Susan M. SHEEHAN, Donald A. MCLEOD, Daryl M. SMITH all of Salt Lake City, Utah in the United States; and Methvin B. ISAAC, and Abdelmalik SLASSI of Mississauga, Ontario, Canada, by an assignment recorded April 2, 2002 at Reel 012758, Frames 0798-0800, have assigned their full and exclusive right in and to the invention set forth in U.S. Application Serial No. 10/076,618 filed February 19, 2002 and entitled HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS to: NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America, this present address of NPS Pharmaceuticals having changed from 420 Chipeta Way, Salt Lake City, Utah, USA;

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned acting with proper authority on behalf of NPS Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City, Utah 84108 United States of America (hereinafter referred to as "ASSIGNOR") hereby sells, assigns, and transfers, unto

AstraZeneca AB SE-151 85 Södertälje, Sweden

(hereinafter referred to as "ASSIGNEE") its successors and assigns, equal, undivided and joint 50% exclusive rights, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to:

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application Serial No. 10/076,618 filed February 19, 2002, as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified application and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, including but not limited to the list of applications shown in Table A below, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

TABLE A

Application #:	Filing Date	Country Code
2002306517	19-Aug-2003	AU
PI0207390-0	20-Aug-2003	BR
2,438,991	20-Aug-2003	CA
2221-2005	31-Aug-2005	CL
02808416.0	19-Feb-2002	CN
03071563	20-Aug-2003	СО
02787093.0	19-Sep-2003	EP
04103079.4	30-Apr-2004	HK
W-00200301831	18-Sep-2003	ID
157,491	20-Aug-2003	IL
01328/DELNP/2003	21-Aug-2003	IN
1252/DEL/2003	10-Oct-2003	IN
6922	20-Aug-2003	IS
2002-567930	19-Aug-2003	JР
10-2003-7010972	21-Aug-2003	KR
PA/a/2003/007513	21-Aug-2003	MX
20033711	19-Feb-2002	NO
527691	19-Aug-2003	NZ
1-2003-500762	12-Aug-2003	PH
P-369598	20-Aug-2003	PL
2003128535	22-Sep-2003	RU
200305450-9	19-Aug-2003	SG
2003088019	27-Aug-2003	UA
60/269,847	21-Feb-2001	US
10/076,618	19-Feb-2002	US
10/699,563	03-Nov-2003	US
PCT/US02/04689	19-Feb-2002	WO
2003/6493	20-Aug-2003	ZA

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including

evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **BIRCH**, **STEWART**, **KOLASCH** & **BIRCH**, **LLP**, the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of BIRCH, STEWART, KOLASCH & BIRCH, LLP, do not personally represent ASSIGNOR OR ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAM	MES AND SIGNATURES O	F ASSIGNOR	
NPS Pharmaceuticals, Inc.	By:	Date:	
	Name:		
	Title:		
NAM	IES AND SIGNATURES OF	F WITNESSES	
Name:	Signature:	Date:	
Name:	Signature:	Date:	

NA NA	AMES AND SIGNATURES OF ASSIGNED	E
AstraZeneca AB	By: To Hamu	Date:
	Name: Bo Hasslev	1
	Title: Director IP Finance & IS	
NA	MES AND SIGNATURES OF WITNESSE	ES
Name: Ann-Sofie Sternås	Signature:	Date:
Name: Sonya Celebioglu	Signature:	Date:



JUNE 04, 2002

PTAS

Commissioner for Trademarks Arlington, VA 22202-3513 www.uspto.gov

FOLEY & LARDNER STEPHEN A. BENT WASHINGTON HARBOUR 3000 K STREET, N.W., SUITE 500 WASHINGTON, D.C. 20007-5143



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/04/2002

REEL/FRAME: 012758/0798

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

VAN WAGENEN, BRADFORD C.

DOC DATE: 03/08/2002

ASSIGNOR:

STORMANN, THOMAS M.

DOC DATE: 03/08/2002

ASSIGNOR:

MOE, SCOTT T.

DOC DATE: 03/26/2002

ASSIGNOR:

SHEEHAN, SUSAN M.

DOC DATE: 03/14/2002

ASSIGNOR:

MCLEOD, DONALD A.

DOC DATE: 03/27/2002

ASSIGNOR:

SMITH, DARY L.

DOC DATE: 03/12/2002

ASSIGNOR:

ISAAC, METHVIN B.

DOC DATE: 03/05/2002

012758/0798 PAGE 2

ASSIGNOR:

SLASSI, ABDELMALIK DOC DATE: 03/05/2002

ASSIGNEE:

NPS PHARMACEUTICALS, INC. 420 CHIPETA WAY

SALT LAKE CITY, UTAH 84108-1256

SERIAL NUMBER: 10076618

FILING DATE: 02/19/2002

PATENT NUMBER: ISSUE DATE:

DOROTHY RILEY, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

NPS PHARMACEUTICALS, INC. 420 Chipeta Way Salt Lake City, Utah 84108-1256

its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries in and to the invention in

HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

as set forth in this United States Patent Application

	executed con	currently herewith	
	executed on		
\boxtimes	Serial No.	filed February 19, 2002	

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may be of said inventions, and to testify in any proceedings relating to said inventions, patent applications and Letters Patent.

ASSIGNMENT - WORLDWIDE Attorney Docket No. 085747/0207

The undersigned hereby grant the firm of FOLEY & LARDNER the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

NAMES AND SIGNATURES OF INVENTORS			
Name: Bradford C. Van Wagenen	Signature: Beall Mally	Date: March 6, 2002	
Name: Thomas M. Stormann	Signature: Same che Strong	Date: March 8, 2002	
Name: Scott T. Moe	Signature: Scott 725	Date: 3-26-02	
Name: Susan M. Sheehan	Signature: SAWALL	Date: March 14, 2002	
Name: Donald A. McLeod	Signature: Dall Wold	Date: 27 March 2002	
Name: Daryl L. Smith	Signature: May I Smith	Date: 12 March 2002	
Name: Methvin B. Isaac	Signature: Marce	Date: 5th March 2011.	
Name: Abdelmalik Slassi	Signature:	Date: March 08/2002	
Name:	Signature:	Date:	
Name:	Signature:	Date:	
NAMES AND SIGNATURES OF WITNESSES			
Name: LeGlies. Lancaster	Signature: Using limante	Date: 8 march 2002	
Name: LOSlies. Lancaster	Signature: Whi S. Luncustr	Date: 27 March 2002	

Note: Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.

IPT-407:4/90(1)(modified)

_		Atty. Dkt. No. 085747-0207	
FCRM PTO-1E95 (modified) 04 - 10	-2002	U.S. DEPARTMENT OF COMMERCE	
	HINIMIN EET	Patent and Trademark Office	
APR 0 4 2002		•	
To the Director of the Chited States atent and Trademark Utilice:	9037 Please record the attached or	iginal documents or copies thereof.	
Name of conveying party(ies):	2. Name and address of	receiving party(ies):	
Bradford C. Van Wagenen (March 8,2002) Thomas M. Stormann (March 8, 2002) Scott T. Moe (March 26, 2002) Susan M. Sheehan (March 14, 2002) Donald A. McLeod (March 27, 2002) Daryl L. Smith (March 12, 2002) Methvin B. Isaac (March 5, 2000) Abdelmalik Slassi (March 5, 2002) Additional conveying party(ies) NO H. H. J.	NPS PHARMACEUTIO 420 Chipeta Way Salt Lake City,		
ASSIGNMENT			
Execution Date:	Additional name(s) & add	ress(es) NO	
See Above	attached?	1033(03)	
4. Application number(s) or patent number(s):			
If this is being filed together with a new application, the A. Patent Application Number(s): 10/076,618	execution date of the appli		
Additional number			
Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of appli involved:	т	
Stephen A. Bent FOLEY & LARDNER Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143	7. Total fee (37 C.F.R. § X Check Enclosed Charge to deposit ac 8. Deposit account	<i>'</i>	
DO NOT USE	number:		
של אטו של	TING OF AGE		
9. Statement and signature: To the best of my knowledge and belief, the foregoing is a true copy of the original document. The Commissioner fees which may be required in this matter to the above-iden	is hereby authorized to cha	correct and any attached copy arge any additional recordation	
Stephen A. Bent	1. Hent	April 4, 2002	
Name of person signing	Signature	Date	
Total number of pages including cover sheet, attachments, and document: 3			

{

02.808232.1